India's auto sector least impacted by rare earth curbs; EVs, hybrids hit hardest: Report
While rare earth magnets are utilised by a wide range of industries, the biggest effect of the restrictions will be felt in the EV sector. (Bloomberg)
Notify me
India's auto sector is least impacted by the recent curb of rare earth magnets by China as over 95 per cent of vehicles in India's are internal combustion engine (IC) vehicles noted a report by Nuvama.
Electric vehicles (EVs), along with hybrid passenger vehicles and electric two-wheelers, are likely to face the most impact from restrictions on rare earth materials (REMs).
The report explained that while REMs are used in a wide range of industries, the biggest effect of the restrictions will be felt in the EV sector, particularly in EV motors.
It stated "The greatest impact of the above restriction in descending order will be electric PVs, hybrid PVs, and electric 2W. Conventional ICE vehicles will be least impacted".
In India, EV adoption is still at an early stage, with penetration at just 7 per cent for two-wheelers and 3 per cent for passenger vehicles.
Although EV sales have grown at a strong compound annual growth rate (CAGR) of 25 per cent between FY23 and FY25, the growth is on a low base. Therefore, even if sales decline, the overall effect on the Indian auto sector is expected to be limited.
Also Read : UP Govt to set up ₹ 700 crore EV park in Kanpur with R&D and logistics connectivity
Most electric vehicles use Permanent Magnet Synchronous Motors (PMSMs), which rely on REMs to maintain a stable magnetic field, especially at high temperatures. The use of PMSMs is far higher in EVs compared to hybrid or ICE vehicles.
As per the report, the average REM usage per vehicle is around 0.8 kg for electric vehicles, 0.5 kg for hybrid vehicles, and just 0.1 kg for ICE vehicles.
Hence, the impact of the restrictions will be the highest on electric passenger vehicles, followed by hybrid passenger vehicles, and then electric two-wheelers. Conventional ICE vehicles will see minimal impact.
In April, China imposed restrictions on the export of seven key rare earth elements: samarium, gadolinium, terbium, dysprosium, lutetium, scandium, and yttrium.
These elements are essential in producing magnets like neodymium iron boron (NdFeB) and samarium-cobalt (SmCo), which are used in various applications including EVs. China currently controls over 90 per cent of global processing of rare earth elements, giving it significant control over the global REM supply chain.
Though the restrictions are mainly aimed at the defence sector, the ripple effects will be seen across the auto, industrial, and aerospace industries.
Auto manufacturers will now need to get end-user certification from the Chinese government to continue sourcing these materials. The process is expected to take around 45 days.
Get insights into Upcoming Cars In India, Electric Vehicles, Upcoming Bikes in India and cutting-edge technology transforming the automotive landscape.
First Published Date: 17 Jun 2025, 09:33 AM IST
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
33 minutes ago
- Mint
Four Indian pharma stocks that may be hit by US pharma tariff threat
Indian pharma stocks took a beating on Tuesday, 17 June, after US President Donald Trump said tariffs on pharmaceutical imports are coming 'very soon." His comments sent shockwaves across the market, dragging the Nifty Pharma index down by over 2% intraday. It was the worst-performing sector of the day. This isn't the first time Trump has hinted at such a move. He had dropped clues back in April, but this latest announcement has added urgency and concern. The Indian pharma industry, which relies heavily on exports to the US for generics and speciality drugs, is now facing concerns over potential revenue disruptions. Any disruption in trade or pricing could have a direct impact on revenues and margins. In this article, we take a look at five Indian pharmaceutical companies that could be the most affected by the proposed US tariffs. #1 Granules India Granules India has a presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies paracetamol, metformin, guaifenesin, and methocarbamol APIs. It has over 10 manufacturing facilities, approximately eight of which are located in India and two in the US. The company sells its products in global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. As per the FY24 annual report, 66% of Granules India's total revenue came from North America. This dependence has only deepened in recent quarters with the US market contributing 79% of revenue in the March 2025 quarter, according to the latest investor presentation. Data Source: Earnings Presentation FY25 and Q4 FY25 Given this significant exposure, any tariff-related cost increases could affect both the company's topline and margins. On 17 June 2025, executive director Priyanka Chigurupati said that the company is currently in the final stages of completing remediation work at its Gagillapur facility. It expects this process to wrap up in the next few months, after which a USFDA re-inspection is anticipated. Once this hurdle is cleared, Granules is aiming to launch 11 pending products in the US market, which were temporarily held back during the compliance phase. Production had been scaled down to prioritise remediation, but the company is now preparing to ramp up volumes again as operations stabilise. It's also working on its first major oncology product launch in the US, expected around FY28. To support its future growth strategy, the company is prepping its Genome Valley facility to meet upcoming USFDA and European audits. #2 Gland Pharma Gland Pharma has become a leader in generic injectables. Its presence spans 60 countries, including the US, Europe, Canada, and Australia. The company's business model primarily involves business-to-business, which contributes 98% of its revenue. It provides contract development, dossier compilation, and technology transfer services. The balance comes from business to consumer. Geographically, the company has a strong presence in the US, which contributes 54% of its revenue. Its revenue in the region has grown from ₹2,585 crore in FY22 to ₹3,037 crore in FY24. This makes the company vulnerable to tariffs. Recently, Gland Pharma received approval from the US Food and Drug Administration (US FDA) for Angiotensin II Acetate Injection. Since the company is the first to submit for exclusivity, it qualifies for 180 days of exclusivity for the generic drug. #3 Aurobindo Pharma Aurobindo Pharma has built a strong presence across more than 150 countries, manufacturing generic formulations, APIs, and injectables. It's the largest generic drug company in the US and ranks among the top 10 generic players in eight European countries. That's where the concern comes in. According to its FY24 annual report, half (48%) of Aurobindo's revenue comes from the US. Data Source: Aurobindo Pharma Annual Report 2023-24 As per the company's investor presentation in March 2025, it holds the top spot in the US in terms of oral solids prescription volume, commanding a 10.5% market share in the September 2024 quarter. So, when talk of new US tariffs on pharma imports hits the headlines, Aurobindo's heavy exposure naturally makes the stock vulnerable to a fall. On 16 June 2025, the company announced the incorporation of a new wholly owned subsidiary, Cresedemo Pharma LLC, in the US. This move aims to further strengthen its US pharma business. While the new entity signals Aurobindo's long-term commitment to the US market, the proposed tariffs could present near-term headwinds for the company. Looking ahead, Aurobindo is placing a big bet on the future of biosimilars. With 14 promising products currently in the pipeline, the company is eyeing a massive US$ 50 bilion+ market opportunity. If things go as planned, this could open up an exciting new growth path and offer some much-needed cushion against any potential policy shocks like the proposed US tariffs. Also Read: India seeks financial details of pharmaceutical marketing practices, industry caught in a bind #4 Dr Reddy's Laboratories Dr Reddy's Lab is one of India's largest pharmaceutical firms in the country. The company manufactures a wide range of pharmaceuticals with expertise spanning several therapeutic areas. Through its step-down subsidiary Aurigene Pharmaceutical Services Ltd (APSL), it's making strong strides in the CDMO space. APSL acts as a comprehensive Contract Research, Development, and Manufacturing Organization (CRO/CDMO), offering end-to-end solutions to global pharmaceutical and speciality companies. It has cGMP manufacturing facilities in the UK, Mexico, USA, and India, enabling it to serve a global clientele. Despite this global footprint, a large chunk of Dr Reddy's revenue still comes from the US. Also, the latest investor presentation of Q4FY25, shows 42% of the total revenue from the US market. This heavy dependence on the US leaves the company exposed to the potential impact of new tariffs. In response to increasing tariff speculation, the company has indicated a desire to consider local manufacturing in the US, through acquisitions. This will not only help reduce the risk of import duties but will also deepen its foot in one of its most important markets. Meanwhile, Dr Reddy focuses on maintaining its growth. The company plans to launch 15-20 new products in the US every year. Also Read: Dr. Reddy's focused on securing supply chains amid US tariff uncertainty Conclusion While the possibility of imports has rattled the sector, it's important to take a balanced view before making investment decisions. There's no denying that companies with high revenue exposure to the US, like Aurobindo Pharma, Granules India, and Dr Reddy's could face near-term challenges if such tariffs are implemented. Margins may come under pressure and growth plans might require changes. However, the long-term fundamentals of India's pharmaceutical industry remain strong. The government is actively supporting the sector through key initiatives such as the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, Promotion of Bulk Drug Parks, Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS), and the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), which aims to make quality medicines accessible at affordable prices. Moreover, according to a recent EY-FICCI report, the Indian pharmaceutical market is poised to reach a value of around $130 billion by 2030, signalling strong growth potential. It's important to conduct thorough research on financials and corporate governance before making investment decisions, ensuring they align with your financial goals and risk tolerance. Happy Investing. Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. This article is syndicated from
Hans India
43 minutes ago
- Hans India
Strong demand, stable activity in economy
India's economic indicators are becoming more supportive of growth, according to the report released by Motilal Oswal Private Wealth (MOPW) on Friday. The report highlights that several positive trends are emerging on the domestic front, including higher GDP growth, easing inflation, and strong tax GDP grew by 7.4 per cent in the fourth quarter of FY25, which is the highest reading in the last four has remained below 4 per cent for four consecutive months, and GST collections have been rising steadily. These signs indicate strong demand and stable activity in the formal sector of the report also notes that India's policy environment is now moving in a unified direction. Fiscal, monetary, and regulatory policies are all aimed at maintaining growth increased tax exemption limits that came into effect from April 2025 are expected to improve disposable incomes and boost the same time, the government's capital expenditure continues to rise, supporting the investment the global front, the environment remains mixed. In April and May, markets faced worries over tariffs and geopolitical tensions. However, the situation improved with a delay in global tariff implementation and a ceasefire announcement between India and Pakistan. This improved global sentiment has helped global equity markets, with the MSCI World Index reaching record highs. Meanwhile, rising bond yields in Japan and China's shift towards gold show that global investors are moving away from US could become a concern as the US faces refinancing of $9 trillion in debt this a weaker Dollar Index could help emerging markets like India by attracting more foreign investments. In the Indian stock market, valuations have increased as earnings have not grown at the same Nifty-50's one-year forward valuation has risen above its long-term average, and mid and small-cap stocks continue to trade at a premium. This makes careful stock selection and active management more important for investors looking to generate higher returns, the report stated.
Hans India
an hour ago
- Hans India
Middle East conflict no major worry: Crisil
The impact of the Middle East tensions on most Indian companies is expected to be limited in the near-term, with low capex intensity and balance sheet strength of firms offering a cushion from potential vulnerabilities, according to a Crisil report released on Friday. However, a prolonged escalation could aggravate the impact mainly due to a rise in oil prices and disruption in supply chains which could stoke inflation, the report added. 'So far, the ongoing uncertainties in the Middle East have not had any significant impact on India Inc's global trade. However, if the situation deteriorates, some sectors such as basmati rice could see a heightened impact and will require monitoring, while others like fertilisers and diamonds — both cut and polished — may also see some impact,' the report stated. Also, prolonged and increasing uncertainties can result in a rise in air/sea freight cost and insurance premiums for export/import-based sectors, the report states. India's direct trade with Israel and Iran is minuscule at less than 1 per cent of the total trade. While India's major export to Iran is basmati rice, trade with Israel is more diversified, and includes fertilisers, diamonds and electrical and Israel accounted for around 14 per cent of India's basmati rice exports in fiscal 2025. But because basmati rice is a staple, the impact on demand due to the ongoing tensions is likely to be limited, according to the Crisil report. Additionally, India's ability to export to other countries in the Middle East, the US and Europe reduces demand risk. But a prolonged crisis can lead to possible delays in payment from counterparties in these regions, elongating the working capital cycle, the report domestic diamond polishers, Israel is mainly a trading hub, accounting for about 4 per cent of the total diamond exports last fiscal. Additionally, around 2 per cent of all rough diamonds imported are from Israel. Polishers also have alternative trading hubs such as Belgium and the United Arab Emirates, with ultimate buyers based in the US and Europe, which will help them to manage any adverse impact on the sector, the report states. Repercussions of any further significant increase in the crude oil prices from the current levels would vary across oil prices will benefit upstream oil companies because it translates to more revenue, while their costs are downstream oil refiners, operating margins could get squeezed due to higher input cost as they may have limited ability to fully pass on the same through increase in retail fuel aviation companies, fuel accounts for about 35-40 per cent of operating cost. Further, the operators will also witness higher fuel cost due to increased travel time on account of airspace closures/diversions.
